is "Oracle Nutraceuticals" the MJ company SB is
Post# of 40991
(Total Views: 481)
Posted On: 12/16/2017 5:24:28 PM
is "Oracle Nutraceuticals" the MJ company SB is
considering acquiring???
https://investorshub.advfn.com/boards/read_ms...=136945723
https://www.sec.gov/Archives/edgar/data/16463..._1012g.htm
"Petroleum Analytics International, Inc. (“PAI” or the “Company”) was organized to acquire and commercialize the intellectual property (“IP”) developed by Mr. Jim Lysyk, a director and officer of the Company. It was reincorporated in Colorado from Delaware in April 2014 and was formerly named Oracle Nutraceuticals Company.
On January 5, 2015, the Company entered into a merger transaction with ONCO Merger Sub, Inc., a then newly- established Colorado corporation, whereby the successor company (ONCO Merger Sub, Inc.) changed its name to Oncology Med, Inc.
On January 5, 2015, the Company effected a share exchange with a newly-established corporation, named Oracle Nutraceuticals Company, whereby Oracle Nutraceuticals issued 100 shares of its common stock in exchange for all of the issued and outstanding shares of Oncology Med, Inc., a Colorado corporation. This transaction became effective pursuant to a reorganization under the applicable provisions of Section 368(a) et seq. of the IRS Code of 1986, as amended. As the result of the reorganization, the public trading company, formerly known as Oncology Med, Inc., a Delaware corporation, and, subsequently, a Colorado corporation, became a wholly-owned subsidiary of Oracle Nutraceuticals Company while Oracle Nutraceuticals Company is deemed the successor entity which is now the reporting and publicly trading entity. As a result of this January 2015 reorganization, the liabilities of Oncology Med, Inc., $221,916 of the $261,916 payables, are at the wholly-owned subsidiary level."
considering acquiring???
https://investorshub.advfn.com/boards/read_ms...=136945723
https://www.sec.gov/Archives/edgar/data/16463..._1012g.htm
"Petroleum Analytics International, Inc. (“PAI” or the “Company”) was organized to acquire and commercialize the intellectual property (“IP”) developed by Mr. Jim Lysyk, a director and officer of the Company. It was reincorporated in Colorado from Delaware in April 2014 and was formerly named Oracle Nutraceuticals Company.
On January 5, 2015, the Company entered into a merger transaction with ONCO Merger Sub, Inc., a then newly- established Colorado corporation, whereby the successor company (ONCO Merger Sub, Inc.) changed its name to Oncology Med, Inc.
On January 5, 2015, the Company effected a share exchange with a newly-established corporation, named Oracle Nutraceuticals Company, whereby Oracle Nutraceuticals issued 100 shares of its common stock in exchange for all of the issued and outstanding shares of Oncology Med, Inc., a Colorado corporation. This transaction became effective pursuant to a reorganization under the applicable provisions of Section 368(a) et seq. of the IRS Code of 1986, as amended. As the result of the reorganization, the public trading company, formerly known as Oncology Med, Inc., a Delaware corporation, and, subsequently, a Colorado corporation, became a wholly-owned subsidiary of Oracle Nutraceuticals Company while Oracle Nutraceuticals Company is deemed the successor entity which is now the reporting and publicly trading entity. As a result of this January 2015 reorganization, the liabilities of Oncology Med, Inc., $221,916 of the $261,916 payables, are at the wholly-owned subsidiary level."
(0)
(0)